Nuvation Bio (NYSE: NUVB)
$3.70
(14.8%)
$0.48
Price as of September 30, 2025, 3:58 p.m. ET
Nuvation Bio Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Nuvation Bio Company Info
Nuvation Bio, Inc. is a biopharmaceutical company tackling some of the unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its proprietary portfolio includes six novel and mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer. The company was founded by David Hung on March 20, 2018 and is headquartered in New York, NY.
News & Analysis
Featured Article
Why Nuvation Bio Stock Is Skyrocketing Today
The bulls are lining up on Wall Street for this up-and-coming biotech stock.
Keith Speights | Sep 30, 2025
Featured Article
NUVB Sales Jump 1,043% on Drug Launch
Motley Fool Markets Team | Aug 7, 2025
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.